发明名称 |
Treatment of circadian rhythm disorders |
摘要 |
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
申请公布号 |
US9060995(B2) |
申请公布日期 |
2015.06.23 |
申请号 |
US201414301799 |
申请日期 |
2014.06.11 |
申请人 |
Vanda Pharmaceuticals, Inc. |
发明人 |
Dressman Marlene Michelle;Feeney John Joseph;Licamele Louis William;Polymeropoulos Mihael H. |
分类号 |
A61K31/343;A61K31/00;G01N33/68 |
主分类号 |
A61K31/343 |
代理机构 |
Hoffman Warnick LLC |
代理人 |
Hoffman Warnick LLC |
主权项 |
1. A method of entraining a light perception impaired patient suffering from Non-24-Hour Sleep-Wake Disorder to a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, wherein the patient is being treated with fluvoxamine, the method comprising:
(A) discontinuing the fluvoxamine treatment and then (B) orally treating the patient with 20 mg of tasimelteon once daily before a target bedtime, thereby avoiding the use of tasimelteon in combination with fluvoxamine. |
地址 |
Washington DC US |